India Favipiravir market is projected to show a robust growth in the forecast period, FY2023 - FY2027, with an impressive CAGR, on account of rising demand for effective and efficient drugs and therapeutics for the viral infection like COVID-19. The drug is being manufactured and marketed in large scale for its effectiveness in controlling mild to moderate COVID-19 infection. Moreover, the drug is also effective in the treatment of viral infections from Ebola virus and Influenza A & B viruses. All these advantages of Favipiravir has led to an increase in the growth of the India Favipiravir market. Also, after the approval to new market players like Lupin, and Vivimed Ltd. the market growth is anticipated to boost in the next five years. With consistent technological advancement and governmental support towards the extensive research and development of the efficient drugs, the market is expected to register its exponential CAGR growth in the upcoming five years. Although, rapidly emerging drugs from the export pathway may put a minor restraint on the market growth in the upcoming five years.
The India Favipiravir market is segmented on the basis of route of administration, dosage form, distribution channel, application, source, regional distribution, and competitional landscape. Based on route of administration, the market is further bifurcated into oral and intravenous administrations. Intravenous administrations are the method of injecting the drug in a solution form in the veins of the patient. The method is anticipated to be more effective over oral administrations of any drug. Oral administrations involve intake of tablets. The
Holding the largest shares of the India Favipiravir market, a partial list of the established market players includes Cipla Ltd., Glenmark Pharmaceuticals Ltd., Sun Pharmaceuticals Industries Ltd., Zendara Pharma Ltd., Indoco Remedies Ltd., Curequest Lifescience India Pvt. Ltd., Gonane Pharma Ltd., Lee Pharma Ltd., Hetero Labs Pvt. Ltd., Dr. Reddy’s Laboratories Ltd, among others. The pharmaceutical companies are in close contact with the research and development institutes that are consistently developing the better and efficient therapeutics and drugs like Favipiravir to overcome the impact of the pandemic. Technological advancement and advanced research techniques are being implemented and pharmaceutical companies are making sure that they have the approval from the governmental authorities to manufacture and market the drugs and the therapeutics on a larger scale.
Years considered for this report
Historical YearsFY2017 – FY2020
Base YearFY2021
Estimated YearFY2022E
Forecast PeriodFY2023F – FY2027F
Objective of the Study
o
o
o
o
o
o
o
o
Click here to download the sample
TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers, suppliers, across the country. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufactures which could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufactures, distribution channels and presence of all major players across the country.
TechSci Research calculated the market size of India
Key Target Audience
o
o
o
o
The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, suppliers, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.
